{
    "clinical_study": {
        "@rank": "99319", 
        "arm_group": [
            {
                "arm_group_label": "Gemigliptin", 
                "arm_group_type": "Placebo Comparator", 
                "description": "only Gemiglitpin (Gemiglitpin/Rosuvastatin FDC:Placebo , Rosuvastatin :Placebo)"
            }, 
            {
                "arm_group_label": "Rosuvastatin", 
                "arm_group_type": "Placebo Comparator", 
                "description": "only Rosuvastatin (Gemiglitpin/Rosuvastatin FDC:Placebo , gemigliptin :Placebo)"
            }, 
            {
                "arm_group_label": "FDC", 
                "arm_group_type": "Experimental", 
                "description": "Gemigliptin & Rosuvastatin (Gemiglitpin only:Placebo ,Rosuvastatin only:Placebo)"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the efficacy and safety of the fix-dose combination therapy with Gemigliptin\n      50mg and Rosuvastatin 20mg with type 2 diabetes and dyslipidemia"
        }, 
        "brief_title": "Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3", 
        "condition": [
            "Type 2 Diabetes", 
            "Dyslipidemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Dyslipidemias"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 2 Diabetes Mellitus with Dyslipidemia\n\n          -  Adults who are at least 19 years old\n\n        Exclusion Criteria:\n\n          -  Patients with type 1 diabetes, diabetic ketoacidosis, diabetic coma and pre-coma\n\n          -  Patients with gestational diabetes or secondary diabetes\n\n          -  Patients with NYHA Class III, IV congestive heart failure or arrhythmias requiring\n             treatment\n\n          -  Patients with thyroid gland dysfunction deviating from the normal TSH range\n\n          -  Patients with pituitary insufficiency or adrenal insufficiency"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "290", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02126358", 
            "org_study_id": "LG-GSCL002"
        }, 
        "intervention": {
            "arm_group_label": [
                "Gemigliptin", 
                "Rosuvastatin", 
                "FDC"
            ], 
            "intervention_name": "Gemigliptin and/or Rosuvastatin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Rosuvastatin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 29, 2014", 
        "location": {
            "contact": {
                "last_name": "SungKyung Kim, Project Manager", 
                "phone": "+82-2-2010-4577"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Severance hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of the Fix-dose Combination Therapy With Gemigliptin 50mg and Rosuvastatin 20mg With Type 2 Diabetes and Dyslipidemia", 
        "overall_contact": {
            "email": "yklee@lgls.com", 
            "last_name": "YoungKyoung Lee, study leader", 
            "phone": "+82-2-6924-3117"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "HbA1c change", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline(Day 0) to Treatment (last visit, w24)"
            }, 
            {
                "measure": "LDL-C change rate", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline(Day 0) to Treatment (last visit, w24)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02126358"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "(Gemigliptin/Rosuvastatin FDC vs. Gemigliptin)", 
                "measure": "HbA1c", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline(Day 0) to Treatment (last visit, w24)"
            }, 
            {
                "description": "(Gemigliptin/Rosuvastatin FDC vs. Rosuvastatin)", 
                "measure": "LDL-C change rate", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline(Day 0) to Treatment (last visit, w24)"
            }
        ], 
        "source": "LG Life Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LG Life Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}